Sofinnova

Percutaneous aortic valve replacement is a technology breakthrough for patients who will need only a few days of hospitalisation.

Diallertest® Milk is becoming the standard of diagnostic for young children milk allergy. DBV is developping this VIASKIN® technology to diagnose and treat other allergies like peanuts…

Nanobodies®, derived from natural single chain antibodies in Camelides, will be the next generation therapeutic antibodies. The anti-TNFalpha is the first under clinical investigation.

Alosteric modulation of m-gluR receptors is on the forefront of innovations for new CNS drugs and specifically for anxiety, depression and schizophrénia.

Producing glyconjugates in a single step is the challenge GlycoVaxyn is facing in order to get vaccins cheaper and easier to produce.